Scorpius Holdings

Scorpius Holdings FCF Yield

Delisted·Sep 11, 2026

The Free Cash Flow Yield of Scorpius Holdings (SCPX) as of Nov 5, 2026 is -109,914.53 %. In the previous year, Free Cash Flow Yield was -137,049.32 % — a change of -19.80% (higher).

FCF Yield

-109,914.53 %

YoY

-19.80%

Last updated:

Free Cash Flow Yield of Scorpius Holdings is 2024 -109,914.53 % . Free Cash Flow Yield of Scorpius Holdings was 2023 -137,049.32 % . It decreases by -19.80% higher compared to the previous year.

The Scorpius Holdings FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2017
-26,025.49 USD
Jan 1, 2018
-90,051.29 USD
Jan 1, 2019
-53,397.48 USD
Jan 1, 2020
-91,423.03 USD
Jan 1, 2021
-163,689.82 USD
Jan 1, 2022
-105,566.35 USD
Jan 1, 2023
-137,049.32 USD
Jan 1, 2024
-109,914.53 USD
The Scorpius Holdings FCF Yield history
YEARFCF YieldYoY
-109,914.53 %-19.80%
-137,049.32 %+29.82%
-105,566.35 %-35.51%
-163,689.82 %+79.05%
-91,423.03 %+71.21%
-53,397.48 %-40.70%
-90,051.29 %+246.01%
-26,025.49 %-53.09%
-55,483.72 %-22.74%
-71,811.75 %+70.71%
-42,066.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scorpius Holdings Stock analysis

What does Scorpius Holdings do? Scorpius Holdings Inc develops immunotherapies targeting cancer through T-cell activation. The company utilizes ImPACT and ComPACT platform technologies to create product candidates such as HS-410 for non-muscle invasive bladder cancer and HS-110 combined with nivolumab for non-small cell lung cancer. Phase II and Ib trials are ongoing for these treatments, focusing on clinical development rather than commercial sales. The firm operates as a clinical stage company without public revenue streams from its products. Scorpius Holdings Inc's business model centers on advancing its pipeline through clinical trials. It does not sell products directly but relies on partnerships and future licensing deals. The company's immuno-oncology focus includes developing therapies like HS-120 for non-small cell lung cancer using ComPACT technology. Clinical trials are conducted to demonstrate efficacy before potential commercialization. The company's revenue model is based on future pharmaceutical partnerships rather than current product sales. It does not generate income from HS-410, HS-110, or HS-120 as these are still in clinical development. Scorpius Holdings Inc's financial strategy involves securing funding through its IPO and potential future equity offerings to support ongoing trials and development. Scorpius Holdings is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scorpius Holdings stock

Free Cash Flow Yield of Scorpius Holdings is -109,914.53 % in 2024.

Free Cash Flow Yield of Scorpius Holdings changed from -137,049.32 % to -109,914.53 %, representing a -19.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Scorpius Holdings since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Scorpius Holdings with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Scorpius Holdings

All Key Metrics — Scorpius Holdings